A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
Active, not recruiting · Phase 1 · NCT02099058
Conditions: Advanced Solid Tumors Cancer
At a glance
- Research payments reported, 2025
- $120
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 237
About the trial
- Sponsor
- AbbVie
- Tested
- Osimertinib (drug), Nivolumab (drug), Telisotuzumab vedotin (drug), Telisotuzumab vedotin (drug), Erlotinib (drug)
- Dates
- Started 2014-01-15; completion 2026-08
- Results posted
- Not yet
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
From ClinicalTrials.gov, last updated 2025-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $120 in research payments for this study in 2025 (3 payments).
Products named: Emrelis
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Raquel O. Alencar, M.D., PH.D. Radiology · Boston, MA
- Michael L. Steigner, M.D. Radiology · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Brigham and Womens Physicians Organization $80
- Scientia Imaging LLC $40
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.